SYNTARA LIMITED - Announcements

Market Cap $27.46M Add to my watchlist

Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug... Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.More

Announcements

Filter Results

All Price Sensitive Only

SNT	Clarification Announcement	PRICE SENSITIVE	13/05/22	305.36KB	Share
SNT	Investor Presentation		29/04/22	934.36KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	29/04/22	496.87KB	Share
SNT	Appendix 4C Quarterly Cash Flow Report	PRICE SENSITIVE	29/04/22	193.55KB	Share
SNT	Pharmaxis Quarterly Investor Briefing		26/04/22	126.62KB	Share
SNT	R&D Showcase Presentations Webinar 2		31/03/22	4.78MB	Share
SNT	R&D Showcase Presentations Webinar 1		29/03/22	9.81MB	Share
SNT	Investor Presentation		22/03/22	2.02MB	Share
SNT	PXS Investor R&D Showcase Webinars		18/03/22	122.17KB	Share
SNT	PXS Launches New International Trial Sites in Cancer Trial		17/03/22	117.79KB	Share
SNT	Change in substantial holding		11/02/22	231.94KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	11/02/22	402.94KB	Share
SNT	Updated Investor Presentation		31/01/22	1.86MB	Share
SNT	Presentation - quarterly investor update		31/01/22	1.05MB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	31/01/22	529.16KB	Share
SNT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	193.78KB	Share
SNT	First Patients Dosed in PXS Scar Reduction Trial		31/01/22	139.82KB	Share
SNT	PXS Quarterly Shareholder Update and Investor Briefing		27/01/22	127.63KB	Share
SNT	Response to ASX Aware Query	PRICE SENSITIVE	10/01/22	392.67KB	Share
SNT	PXS Collaborators Receive Government Grants of $1.4m	PRICE SENSITIVE	06/01/22	156.38KB	Share
SNT	Change of Director's Interest Notice		24/12/21	145.21KB	Share
SNT	Change of Director's Interest Notice		23/12/21	140.98KB	Share
SNT	Change of Director's Interest Notice		23/12/21	143.2KB	Share
SNT	Application for quotation of securities - PXS		22/12/21	25.34KB	Share
SNT	Change of Director's Interest Notice		22/12/21	144.71KB	Share
SNT	Change of Director's Interest Notice		22/12/21	143.53KB	Share
SNT	Application for quotation of securities - PXS		21/12/21	23.1KB	Share
SNT	Share Purchase Plan	PRICE SENSITIVE	20/12/21	145.24KB	Share
SNT	Investor presentation		08/12/21	2.13MB	Share
SNT	Investor Briefing		02/12/21	104.42KB	Share
SNT	Application for quotation of securities - PXS		30/11/21	24.93KB	Share
SNT	Security Purchase Plan	PRICE SENSITIVE	25/11/21	389.6KB	Share
SNT	Section 708A(5)(e) Notice		24/11/21	140.75KB	Share
SNT	Application for quotation of securities - PXS		24/11/21	24.59KB	Share
SNT	Application for quotation of securities - PXS		23/11/21	23.37KB	Share
SNT	Proposed issue of securities - PXS		18/11/21	27.83KB	Share
SNT	Investor Presentation	PRICE SENSITIVE	17/11/21	2.22MB	Share
SNT	Proposed issue of securities - PXS		17/11/21	24.66KB	Share
SNT	Placement	PRICE SENSITIVE	17/11/21	152.6KB	Share
SNT	Trading Halt	PRICE SENSITIVE	15/11/21	228.42KB	Share
SNT	FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study	PRICE SENSITIVE	09/11/21	118.69KB	Share
SNT	Notification regarding unquoted securities - PXS		05/11/21	26.7KB	Share
SNT	Investor Presentation		04/11/21	1.96MB	Share
SNT	Change of Director's Interest Notice		03/11/21	139.49KB	Share
SNT	Notification regarding unquoted securities - PXS		03/11/21	25.58KB	Share
SNT	Constitution as amended 3 November		03/11/21	344.96KB	Share
SNT	Results of Meeting		03/11/21	276.84KB	Share
SNT	CEO Presentation to 2021 AGM		03/11/21	1.41MB	Share
SNT	Chairman's Address to Shareholders		03/11/21	160.48KB	Share
SNT	Investor Presentation - September Quarterly Update		28/10/21	1.15MB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	28/10/21	514.55KB	Share
SNT	Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/21	193.16KB	Share
SNT	Pharmaxis Quarterly Shareholder Update and Investor Briefing		25/10/21	129.28KB	Share
SNT	PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial	PRICE SENSITIVE	13/10/21	116.37KB	Share
SNT	PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial	PRICE SENSITIVE	05/10/21	165.64KB	Share
SNT	Corporate Governance Statement		01/10/21	237.25KB	Share
SNT	Appendix 4G		01/10/21	199.5KB	Share
SNT	Notice of Annual General Meeting/Proxy Form		01/10/21	492.58KB	Share
SNT	Annual Report to shareholders		01/10/21	855.28KB	Share
SNT	Change in substantial holding		27/09/21	421.76KB	Share
SNT	Change in substantial holding		24/09/21	981.14KB	Share
SNT	Pharmaxis to Present at Biotech Webinar		22/09/21	95.03KB	Share
SNT	Application for quotation of securities - PXS		21/09/21	31.68KB	Share
SNT	Notification of cessation of securities - PXS		20/09/21	21.62KB	Share
SNT	Application for quotation of securities - PXS		20/09/21	24.93KB	Share
SNT	Application for quotation of securities - PXS		09/09/21	24.93KB	Share
SNT	Investor Presentation		07/09/21	1.65MB	Share
SNT	Pharmaxis Treatment to Prevent Wound and Burns Scars Clears	PRICE SENSITIVE	31/08/21	133.42KB	Share
SNT	Application for quotation of securities - PXS		26/08/21	27.98KB	Share
SNT	Application for quotation of securities - PXS		20/08/21	24.93KB	Share
SNT	PXS Grants Exclusive Option to Develop High Payload Inhaler	PRICE SENSITIVE	17/08/21	169.14KB	Share
SNT	Notification regarding unquoted securities - PXS		13/08/21	27.31KB	Share
SNT	Proposed Issue of Employee Options		13/08/21	162.33KB	Share
SNT	Change of Director's Interest Notice		13/08/21	144.47KB	Share
SNT	Notification of cessation of securities - PXS		13/08/21	21.69KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	12/08/21	945.3KB	Share
SNT	PXS Drug Decreases Tumour Burden in Liver Cancer Model	PRICE SENSITIVE	05/08/21	132.32KB	Share
SNT	PXS Commences Final Cohort Dosing in Phase 1c Cancer Trial		04/08/21	117.96KB	Share
SNT	Investor Presentation Quarterly Shareholder Update		29/07/21	1022.96KB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/21	1.13MB	Share
SNT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/21	180KB	Share
SNT	Pharmaxis Shareholder Investor Call - Corrected Link		27/07/21	128.46KB	Share
SNT	Pharmaxis Quarterly Shareholder Investor Briefing		27/07/21	128.85KB	Share
SNT	Application for quotation of securities - PXS		07/07/21	24.93KB	Share
SNT	Application for quotation of securities - PXS		07/07/21	24.95KB	Share
SNT	PXS Sells Australian Distribution Rights for A$2m	PRICE SENSITIVE	01/07/21	146.07KB	Share
SNT	BTC: Exclusive distribution rights for Bronchitol & Aridol	PRICE SENSITIVE	30/06/21	118.62KB	Share
SNT	Notification of cessation of securities - PXS		30/06/21	21.63KB	Share
SNT	Application for quotation of securities - PXS		30/06/21	24.93KB	Share
SNT	Change in substantial holding		29/06/21	219.9KB	Share
SNT	PXS Announces First Results in Bone Marrow Cancer Trial	PRICE SENSITIVE	29/06/21	118.64KB	Share
SNT	Change of Director's Interest Notice		29/06/21	154.74KB	Share
SNT	Progression of Clinical Trial in Bone Marrow Cancer		10/06/21	117.07KB	Share
SNT	Investor Presentation - 4 June 2021		04/06/21	2.39MB	Share
SNT	Pharmaxis Investor Briefing		31/05/21	140.42KB	Share
SNT	Change of Director's Interest Notice		04/05/21	145.71KB	Share
SNT	Promising New Drug to Tackle Brain Cancer		03/05/21	137.88KB	Share
SNT	Quarterly Activity Report	PRICE SENSITIVE	30/04/21	498KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/21	179.97KB	Share
SNT	Appendix 2A - Exercise of Employee Options		22/04/21	193.48KB	Share

SNT Clarification Announcement
13/05/22	PRICE SENSITIVE	305.36KB	Share
SNT Investor Presentation
29/04/22		934.36KB	Share
SNT Quarterly Activities Report
29/04/22	PRICE SENSITIVE	496.87KB	Share
SNT Appendix 4C Quarterly Cash Flow Report
29/04/22	PRICE SENSITIVE	193.55KB	Share
SNT Pharmaxis Quarterly Investor Briefing
26/04/22		126.62KB	Share
SNT R&D Showcase Presentations Webinar 2
31/03/22		4.78MB	Share
SNT R&D Showcase Presentations Webinar 1
29/03/22		9.81MB	Share
SNT Investor Presentation
22/03/22		2.02MB	Share
SNT PXS Investor R&D Showcase Webinars
18/03/22		122.17KB	Share
SNT PXS Launches New International Trial Sites in Cancer Trial
17/03/22		117.79KB	Share
SNT Change in substantial holding
11/02/22		231.94KB	Share
SNT Half Yearly Report and Accounts
11/02/22	PRICE SENSITIVE	402.94KB	Share
SNT Updated Investor Presentation
31/01/22		1.86MB	Share
SNT Presentation - quarterly investor update
31/01/22		1.05MB	Share
SNT Quarterly Activities Report
31/01/22	PRICE SENSITIVE	529.16KB	Share
SNT Quarterly Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	193.78KB	Share
SNT First Patients Dosed in PXS Scar Reduction Trial
31/01/22		139.82KB	Share
SNT PXS Quarterly Shareholder Update and Investor Briefing
27/01/22		127.63KB	Share
SNT Response to ASX Aware Query
10/01/22	PRICE SENSITIVE	392.67KB	Share
SNT PXS Collaborators Receive Government Grants of $1.4m
06/01/22	PRICE SENSITIVE	156.38KB	Share
SNT Change of Director's Interest Notice
24/12/21		145.21KB	Share
SNT Change of Director's Interest Notice
23/12/21		140.98KB	Share
SNT Change of Director's Interest Notice
23/12/21		143.2KB	Share
SNT Application for quotation of securities - PXS
22/12/21		25.34KB	Share
SNT Change of Director's Interest Notice
22/12/21		144.71KB	Share
SNT Change of Director's Interest Notice
22/12/21		143.53KB	Share
SNT Application for quotation of securities - PXS
21/12/21		23.1KB	Share
SNT Share Purchase Plan
20/12/21	PRICE SENSITIVE	145.24KB	Share
SNT Investor presentation
08/12/21		2.13MB	Share
SNT Investor Briefing
02/12/21		104.42KB	Share
SNT Application for quotation of securities - PXS
30/11/21		24.93KB	Share
SNT Security Purchase Plan
25/11/21	PRICE SENSITIVE	389.6KB	Share
SNT Section 708A(5)(e) Notice
24/11/21		140.75KB	Share
SNT Application for quotation of securities - PXS
24/11/21		24.59KB	Share
SNT Application for quotation of securities - PXS
23/11/21		23.37KB	Share
SNT Proposed issue of securities - PXS
18/11/21		27.83KB	Share
SNT Investor Presentation
17/11/21	PRICE SENSITIVE	2.22MB	Share
SNT Proposed issue of securities - PXS
17/11/21		24.66KB	Share
SNT Placement
17/11/21	PRICE SENSITIVE	152.6KB	Share
SNT Trading Halt
15/11/21	PRICE SENSITIVE	228.42KB	Share
SNT FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study
09/11/21	PRICE SENSITIVE	118.69KB	Share
SNT Notification regarding unquoted securities - PXS
05/11/21		26.7KB	Share
SNT Investor Presentation
04/11/21		1.96MB	Share
SNT Change of Director's Interest Notice
03/11/21		139.49KB	Share
SNT Notification regarding unquoted securities - PXS
03/11/21		25.58KB	Share
SNT Constitution as amended 3 November
03/11/21		344.96KB	Share
SNT Results of Meeting
03/11/21		276.84KB	Share
SNT CEO Presentation to 2021 AGM
03/11/21		1.41MB	Share
SNT Chairman's Address to Shareholders
03/11/21		160.48KB	Share
SNT Investor Presentation - September Quarterly Update
28/10/21		1.15MB	Share
SNT Quarterly Activities Report
28/10/21	PRICE SENSITIVE	514.55KB	Share
SNT Appendix 4C Cash Flow Report
28/10/21	PRICE SENSITIVE	193.16KB	Share
SNT Pharmaxis Quarterly Shareholder Update and Investor Briefing
25/10/21		129.28KB	Share
SNT PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial
13/10/21	PRICE SENSITIVE	116.37KB	Share
SNT PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial
05/10/21	PRICE SENSITIVE	165.64KB	Share
SNT Corporate Governance Statement
01/10/21		237.25KB	Share
SNT Appendix 4G
01/10/21		199.5KB	Share
SNT Notice of Annual General Meeting/Proxy Form
01/10/21		492.58KB	Share
SNT Annual Report to shareholders
01/10/21		855.28KB	Share
SNT Change in substantial holding
27/09/21		421.76KB	Share
SNT Change in substantial holding
24/09/21		981.14KB	Share
SNT Pharmaxis to Present at Biotech Webinar
22/09/21		95.03KB	Share
SNT Application for quotation of securities - PXS
21/09/21		31.68KB	Share
SNT Notification of cessation of securities - PXS
20/09/21		21.62KB	Share
SNT Application for quotation of securities - PXS
20/09/21		24.93KB	Share
SNT Application for quotation of securities - PXS
09/09/21		24.93KB	Share
SNT Investor Presentation
07/09/21		1.65MB	Share
SNT Pharmaxis Treatment to Prevent Wound and Burns Scars Clears
31/08/21	PRICE SENSITIVE	133.42KB	Share
SNT Application for quotation of securities - PXS
26/08/21		27.98KB	Share
SNT Application for quotation of securities - PXS
20/08/21		24.93KB	Share
SNT PXS Grants Exclusive Option to Develop High Payload Inhaler
17/08/21	PRICE SENSITIVE	169.14KB	Share
SNT Notification regarding unquoted securities - PXS
13/08/21		27.31KB	Share
SNT Proposed Issue of Employee Options
13/08/21		162.33KB	Share
SNT Change of Director's Interest Notice
13/08/21		144.47KB	Share
SNT Notification of cessation of securities - PXS
13/08/21		21.69KB	Share
SNT Preliminary Final Report
12/08/21	PRICE SENSITIVE	945.3KB	Share
SNT PXS Drug Decreases Tumour Burden in Liver Cancer Model
05/08/21	PRICE SENSITIVE	132.32KB	Share
SNT PXS Commences Final Cohort Dosing in Phase 1c Cancer Trial
04/08/21		117.96KB	Share
SNT Investor Presentation Quarterly Shareholder Update
29/07/21		1022.96KB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/21	PRICE SENSITIVE	1.13MB	Share
SNT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/21	PRICE SENSITIVE	180KB	Share
SNT Pharmaxis Shareholder Investor Call - Corrected Link
27/07/21		128.46KB	Share
SNT Pharmaxis Quarterly Shareholder Investor Briefing
27/07/21		128.85KB	Share
SNT Application for quotation of securities - PXS
07/07/21		24.93KB	Share
SNT Application for quotation of securities - PXS
07/07/21		24.95KB	Share
SNT PXS Sells Australian Distribution Rights for A$2m
01/07/21	PRICE SENSITIVE	146.07KB	Share
SNT BTC: Exclusive distribution rights for Bronchitol & Aridol
30/06/21	PRICE SENSITIVE	118.62KB	Share
SNT Notification of cessation of securities - PXS
30/06/21		21.63KB	Share
SNT Application for quotation of securities - PXS
30/06/21		24.93KB	Share
SNT Change in substantial holding
29/06/21		219.9KB	Share
SNT PXS Announces First Results in Bone Marrow Cancer Trial
29/06/21	PRICE SENSITIVE	118.64KB	Share
SNT Change of Director's Interest Notice
29/06/21		154.74KB	Share
SNT Progression of Clinical Trial in Bone Marrow Cancer
10/06/21		117.07KB	Share
SNT Investor Presentation - 4 June 2021
04/06/21		2.39MB	Share
SNT Pharmaxis Investor Briefing
31/05/21		140.42KB	Share
SNT Change of Director's Interest Notice
04/05/21		145.71KB	Share
SNT Promising New Drug to Tackle Brain Cancer
03/05/21		137.88KB	Share
SNT Quarterly Activity Report
30/04/21	PRICE SENSITIVE	498KB	Share
SNT Appendix 4C - quarterly
30/04/21	PRICE SENSITIVE	179.97KB	Share
SNT Appendix 2A - Exercise of Employee Options
22/04/21		193.48KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last 2.3¢		Change -0.003(11.5%)		Mkt cap ! $27.46M

Open	High	Low	Value	Volume
2.5¢	2.6¢	2.3¢	$24.39K	1.023M

Buyers (Bids)

No.	Vol.	Price($)
2	43788	2.3¢

Sellers (Offers)

Price($)	Vol.	No.
2.4¢	182499	2

View Market Depth

No.	Vol.	Price($)
2	43788	0.023
5	155415	0.022
5	793867	0.021
12	3867674	0.020
3	1026988	0.019

Price($)	Vol.	No.
0.024	182499	2
0.025	139960	2
0.027	250000	2
0.029	347870	2
0.030	358058	3

Last trade - 12.55pm 21/06/2024 (20 minute delay)


Last 2.4¢		Change -0.003 ( 7.69 %)
Open	High	Low	Volume
2.5¢	2.5¢	2.3¢	528912
Last updated 13.02pm 21/06/2024 ?

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories